TRCT
INFI

Tower Research Capital (TRC)’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Tower Research Capital (TRC)’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,649
Closed -$5.41K – 6408
2023
Q2 		$5.41K Sell
25,649
-694
-3% -$121 ﹤0.01% 4833
2023
Q1 		$4K Buy
26,343
+1,127
+4% +$501 ﹤0.01% 5148
2022
Q4 		$14K Buy
25,216
+3,140
+14% +$2.67K ﹤0.01% 3558
2022
Q3 		$26K Buy
22,076
+4,839
+28% +$5.22K ﹤0.01% 3738
2022
Q2 		$11K Buy
17,237
+7,862
+84% +$6.04K ﹤0.01% 4409
2022
Q1 		$11K Sell
9,375
-28,561
-75% -$34.1K ﹤0.01% 4241
2021
Q4 		$85K Buy
37,936
+33,030
+673% +$82.9K ﹤0.01% 2344
2021
Q3 		$17K Sell
4,906
-296
-6% -$912 ﹤0.01% 3898
2021
Q2 		$16K Sell
5,202
-25,918
-83% -$82K ﹤0.01% 4099
2021
Q1 		$100K Buy
31,120
+15,701
+102% +$52.4K ﹤0.01% 2585
2020
Q4 		$33K Buy
+15,419
New +$25.4K ﹤0.01% 3501
2020
Q3 		– Sell
-17
Closed – – 5195
2020
Q2 		$0 Buy
+17
New +$16 ﹤0.01% 5074
2020
Q1 		– Sell
-11,829
Closed -$11K – 4150
2019
Q4 		$11K Buy
11,829
+9,363
+380% +$10.3K ﹤0.01% 2300
2019
Q3 		$3K Buy
+2,466
New +$3.36K ﹤0.01% 3612
2019
Q2 		– Sell
-2,703
Closed -$5K – 4487
2019
Q1 		$5K Sell
2,703
-2,745
-50% -$4.02K ﹤0.01% 3111
2018
Q4 		$6K Buy
+5,448
New +$9.8K ﹤0.01% 2834
2018
Q2 		– Sell
-387
Closed -$1K – 4193
2018
Q1 		$1K Sell
387
-1,277
-77% -$2.74K ﹤0.01% 3122
2017
Q4 		$3K Buy
+1,664
New +$3.45K ﹤0.01% 3128
2017
Q3 		– Sell
-35,653
Closed -$44.3K – 4245
2017
Q2 		$56K Buy
+35,653
New +$68.8K 0.01% 704
2016
Q3 		– Sell
-23,159
Closed -$31K – 4670
2016
Q2 		$31K Buy
23,159
+21,659
+1,444% +$101K ﹤0.01% 1917
2016
Q1 		$8K Sell
1,500
-1,155
-44% -$7.07K ﹤0.01% 2262
2015
Q4 		$21K Buy
2,655
+671
+34% +$5.78K ﹤0.01% 1259
2015
Q3 		$17K Sell
1,984
-9,861
-83% -$91K ﹤0.01% 1895
2015
Q2 		$130K Buy
11,845
+2,940
+33% +$37.7K 0.01% 611
2015
Q1 		$124K Buy
8,905
+8,543
+2,360% +$131K 0.02% 728
2014
Q4 		$6K Buy
362
+262
+262% +$3.81K ﹤0.01% 2620
2014
Q3 		$1K Buy
+100
New +$1.19K ﹤0.01% 4190
2014
Q2 		– Sell
-1,623
Closed -$19K – 4777
2014
Q1 		$19K Buy
1,623
+1,223
+306% +$16.4K ﹤0.01% 1950
2013
Q4 		$6K Sell
400
-1,975
-83% -$27.9K ﹤0.01% 3440
2013
Q3 		$42K Sell
2,375
-6,513
-73% -$125K ﹤0.01% 2077
2013
Q2 		$144K Buy
+8,888
New +$275K 0.01% 352

Other funds holding INFI

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Tower Research Capital (TRC)'s INFI Position: Q3 2023 in Review

Tower Research Capital (TRC) sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 25,649 shares — an estimated $5.41K sold.

Tower Research Capital (TRC) first reported a position in INFI in Q2 2013 and held it in 31 quarters. The position peaked at $144K in Q2 2013. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

  • Tower Research Capital (TRC) reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 25,649 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $5.41K.
  • Tower Research Capital (TRC) first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 31 quarters.
  • Tower Research Capital (TRC)'s Infinity Pharmaceuticals, Inc. position peaked at $144K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.